Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma

Kаrmаzаnovsky, G. G.; Belousova, E. L.; Schima, Wolfgang; Глотов, А. В.; Kalinin, D. V.; Kriger, A. G.

doi:10.1016/j.ejrad.2018.04.006

Cited by 34 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MPD dilatation is correlated to both PDACs and PNETs but more likely associated with PDACs. [14–17] A prior study reported that a significant ( P < .01) increase in the MPD dilatation and minimal decrease in mean tumor size emerged among the PDAC patients, compared with PNET patients. [2] Another study described that increased MPD dilatation was in PDAC patients; however, nonsignificant ( P > .05) difference was identified on the ductal dilatation incidence between PDACs and PNETs.…”

Section: Discussionmentioning

confidence: 99%

Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign”

Xiao

Zhi

et al. 2019

Medicine

View full text Add to dashboard Cite

To assess the duct-road sign and tumor-to-duct ratio (TDR) in MRI for differentiating pancreatic neuroendocrine tumors (PNETs) from pancreatic ductal-adenocarcinomas (PDACs).Retrospectively reviewed MRI characteristics of 78 pancreatic masses (histopathology-proven 25 PNETs and 53 PDACs). Receiver operating characteristics with TDR and diagnostic performance of the duct-road sign for differential diagnosis were performed.The prevalence of duct-road sign in PNETs was higher than that for PDACs (84% vs 0%; P < .001). A strong correlation (r = 0.884, P < .001) was observed between MRI for PNETs and the frequency of this sign. Performance characteristics of the duct-road sign in MRI for PNET diagnosis were sensitivity (84%, [21 of 25]), specificity (100%, [53 of 53]), positive predictive value (100%, [21 of 21]), negative predictive value (92.9%, [53 of 57]), and accuracy (94.8%, [74 of 78]). In the intention-to-diagnose analysis, the corresponding values were 67.7% (21 of 31), 100% (53 of 53), 100% (21 of 21), 84.1% (53 of 63), and 88.1% (74 of 84). The TDR in PNETs was observed to be greater than that in PDACs (14.6 ± 9.3 vs 6.9 ± 3.8, P = .001). TDR with a cut-off value of 7.7 had high sensitivity (84%) and specificity (66%) with area under curve (0.802, 95% CI: 0.699, 0.904; P < .001) for distinguishing PNETs from PDACs.The presence of duct-road sign and TDR > 7.7 on MRI may assist in diagnosis for PNET instead of PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign”

Xiao

Zhi

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Pancreatic Neuroendocrine Neoplasms (pNEN) are malignancies arising from the Islets of Langerhans and, therefore, are different from the more frequently occurring exocrine pancreas cancer (1). pNEN represent 7% of all NEN and ~2% of all pancreatic neoplasms with an incidence of 1–2 per 100,000 persons per year (2). pNEN diagnosis is mostly influenced by hormonal hypersecretion that usually leads to early diagnosis due to the manifestation of clinical symptoms (3).…”

Section: Introductionmentioning

confidence: 99%

“…pNEN diagnosis is mostly influenced by hormonal hypersecretion that usually leads to early diagnosis due to the manifestation of clinical symptoms (3). However, since up to 85% of patients do not display a specific syndrome, pNEN are often discovered incidentally at advanced stages or due to the presence of local compressive symptoms (2). Surgical resection remains the most effective treatment, but >50% of NEN are not resectable at diagnosis (4, 5).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line

et al. 2019

View full text Add to dashboard Cite

Pancreatic Neuroendocrine Neoplasms (pNEN) are rare tumors which treatment still represent an important clinical problem, due to the paucity of medical treatments. Due to tumor complexity, techniques as 3D cultures are important to study drug activity in a more realistic model. This study aims to compare three different 3D culture methods in order to understand which one can be considered the best option in terms of experimental easiness and reproducibility in studying the efficacy of a target drug on pNEN. The BON1 cell line was used as a pNEN model and the well-known Receptor Tyrosine Kinase inhibitor Sunitinib was used in order to better investigate the different features of each method. The investigated methods are: (1) 96-well hanging drop plates (HD plates), (2) 24-well plates with a cell-repellent surface, and (3) ultra-low attachment 96-well plates with clear round bottom (ULA plates). The evaluated parameters during the study were: cell seeding, easiness in spheroids formation, morphology, culture maintenance, medium change, spheroids monitoring, picture quality, spheroid perimeter measurement reproducibility error, possibility to perform assays into the seeding plate, overall time of the experiment. Moreover, we investigated how culture methods can influence experimental outcomes evaluating perimeter changes, cell viability and immunohistochemistry of spheroids treated with different Sunitinib concentrations. Results showed that each method has weak and strong points but, considering the easiness of spheroids maintenance and reproducibility results, ULA plates method appears to be the best approach to culture BON1 spheroids and, therefore, to study pNEN.

show abstract

“…Most PNETs are hypervascular masses and are well-circumscribed (4,5). Cystic degeneration, necrosis, and calcification can occur in pancreatic neuroendocrine tumors (6–8). Jeon et al.…”

Section: Introductionmentioning

confidence: 99%

Differentiation between non-hypervascular pancreatic neuroendocrine tumors and mass-forming pancreatitis using contrast-enhanced computed tomography

et al. 2020

View full text Add to dashboard Cite

Background Non-hypervascular pancreatic neuroendocrine tumors (PNETs) showed slight or iso-enhancement in contrast-enhanced computed tomography (CE-CT), which shared similar imaging findings with mass-forming pancreatitis (MFPs). Purpose To explore the value of CT imaging features in differentiating the two diseases. Material and Methods Fifty-one patients with histologically proved MFPs (n = 27) or non-hypervascular PNETs (n = 24) were included. Two radiologists reviewed CT imaging findings and clinical features. Logistic regression analysis was performed to identify relevant features in differentiating non-hypervascular PNETs and MFPs. Receiver operating characteristic (ROC) curve analysis was used to show the performance of the optimal parameters in differentiating non-hypervascular PNETs and MFPs. Results A well-defined margin was more common in non-hypervascular PNETs ( P < 0.05) than that in MFPs. MFPs often occurred in older people ( P < 0.01) and the head–neck of the pancreas compared with non-hypervascular PNETs ( P < 0.05). Metastases only presented in non-hypervascular PNETs ( P < 0.05). CT values at venous phase and delay phase of MFPs were higher ( P = 0.010 and P = 0.029) than those in non-hypervascular PNETs. Logistic analysis showed gender, tumor margin, CT values at venous phase, and tumor components were independent predictors in differentiating the two lesions. The area under the curve (AUC) was 0.938 with a sensitivity of 87.5% and specificity of 92.6% for combined predicators. Conclusion Gender, tumor margin, CT values at venous phase, and tumor components were useful predicators in differentiating non-hypervascular PNETs and MFPs.

show abstract

Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma

Cited by 34 publications

References 19 publications

Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign”

Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign”

Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line

Differentiation between non-hypervascular pancreatic neuroendocrine tumors and mass-forming pancreatitis using contrast-enhanced computed tomography

Contact Info

Product

Resources

About